Zymeworks Inc. (ZYME) is a Biotechnology company in the Healthcare sector, currently trading at $27.73. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is ZYME = $35 (+25% upside).
Valuation: ZYME trades at a trailing Price-to-Earnings (P/E) of -25 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.34.
Financials: revenue is $106M, -14.1%/yr average growth. Net income is $81M (loss), growing at -55%/yr. Net profit margin is -76.6% (negative). Gross margin is 89.8% (+40.4 pp trend).
Balance sheet: total debt is $18M against $269M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 5.52 (strong liquidity). Debt-to-assets is 5.3%. Total assets: $347M.
Analyst outlook: 18 / 20 analysts rate ZYME as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
